$7.11
Closed
-$0.15(-2.06%)
At close
About
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 67 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Key stats
Open
$7.77
Volume
363.66K
Market cap
$0.00
Prev. close
$7.26
Impl / hst vl
-
Open interest
$0.00
$0.00
Day’s Range
$0.00
$4.77
52W Range
$15.43
Valuation
33
Valuation score
Overvalued
P/E
-
P/S
-
P/B
10.61
Current ratio
1.82
Debt / Equity
-1.18
ROE
-211.00%
Gross margin
-
Income growth
15.88%
FCF growth
-18.87
Analysts estimates
Consensus rating
Buy
The average rating from top 12 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$36.55
The top 8 analysts forecasts that 12-month price may increase by 414.00%, with a low of $21.52 and a high of $57.19
$21.52
Low
$36.55
Avg
$57.19
High
Current price
Earnings
Q4 ‘24 revenue
$0.00
Q4 ‘24 net income
-$107.68M
Revenue
Net income
Previous EPS
-Estimate EPS
$0.00
Actual EPS
Estimate EPS